
Benjamin Garmezy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8517330/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precision Oncology, 2022, 6, e2100267.	1.5	28
2	A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. Blood Reviews, 2021, 45, 100691.	2.8	17
3	Combination antiangiogenic tyrosine kinase inhibition and antiâ€PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Medicine, 2021, 10, 2341-2349.	1.3	15
4	All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma. Journal of Bone Oncology, 2021, 31, 100399.	1.0	12
5	Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy Journal of Clinical Oncology, 2020, 38, 3008-3008.	0.8	11
6	Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma Journal of Clinical Oncology, 2020, 38, e17090-e17090.	0.8	0
7	Identifying functional loss of ATM gene in patients with advanced cancer Journal of Clinical Oncology, 2020, 38, 3629-3629.	0.8	1
8	Characterization of Mortality in Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S353.	0.2	1
9	The oncology prognosis and informed consent: Presentation of a new model to best inform patients Journal of Clinical Oncology, 2017, 35, 146-146.	0.8	0
10	Differentiating Skin-Limited and Multisystem Langerhans CellÂHistiocytosis. Journal of Pediatrics, 2014, 165, 990-996.	0.9	77